Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-04
DOI
10.1007/s40264-020-00938-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
- (2019) Mohamed-Eslam F. Mohamed et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
- (2019) Amanda Mogul et al. ANNALS OF PHARMACOTHERAPY
- Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
- (2019) Ben Klünder et al. CLINICAL PHARMACOKINETICS
- Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
- (2019) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
- (2019) Rujia Xie et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism
- (2019) Ji Sang Lee et al. Pharmaceutics
- Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4
- (2019) Xiucai Guo et al. CHEMICAL RESEARCH IN TOXICOLOGY
- An evaluation of tofacitinib for the treatment of psoriatic arthritis
- (2019) Hunar Abdulrahim et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
- (2019) Mohamed‐Eslam F. Mohamed et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
- (2019) Katie Bechman et al. PHARMACOLOGICAL RESEARCH
- “Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4”: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping
- (2019) Vijayabhaskar Veeravalli et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Baricitinib: A Review in Rheumatoid Arthritis
- (2018) Zaina T. Al-Salama et al. DRUGS
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Strategies toward rheumatoid arthritis therapy; the old and the new
- (2018) Mojtaba Abbasi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
- (2018) Mohamed-Eslam F. Mohamed et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Filgotinib for the treatment of rheumatoid arthritis
- (2017) Peter C. Taylor et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials
- (2017) Arnaud Mazouyès et al. JOINT BONE SPINE
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
- (2017) Nicolino Ruperto et al. Pediatric Rheumatology
- Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis
- (2016) Mohamed-Eslam F. Mohamed et al. CLINICAL PHARMACOKINETICS
- Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food
- (2016) Manisha Lamba et al. JOURNAL OF CLINICAL PHARMACOLOGY
- A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective
- (2016) Peter C. Taylor et al. RHEUMATOLOGY INTERNATIONAL
- AB0492 Evaluation of Potential Drug-Drug Interactions with Baricitinib
- (2015) C. Payne et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
- (2015) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
- (2015) Josef S. Smolen et al. Nature Reviews Rheumatology
- 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2015) Jasvinder A. Singh et al. Arthritis & Rheumatology
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
- (2014) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Management of rheumatoid arthritis: the 2012 perspective
- (2014) Hisashi Yamanaka et al. Modern Rheumatology
- A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis
- (2013) Bernard Bannwarth et al. Expert Opinion on Drug Metabolism & Toxicology
- Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end-stage renal disease
- (2013) Sriram Krishnaswami et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data
- (2012) Pankaj Gupta et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy
- (2012) Kris Vaddi et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
- (2011) Jeffrey R. Curtis et al. CLINICAL THERAPEUTICS
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants
- (2010) Sriram Krishnaswami et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites
- (2009) Deepak Dalvie et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Rheumatoid arthritis
- (2009) Lars Klareskog et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now